Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Updates FY 2026 Earnings Guidance

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) updated its FY 2026 earnings guidance on Tuesday morning. The company provided EPS guidance of 1.200-1.346 for the period, compared to the consensus estimate of 1.250. The company issued revenue guidance of $52.1 billion-$54.5 billion, compared to the consensus revenue estimate of $52.1 billion.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on BAYRY. Deutsche Bank Aktiengesellschaft upgraded Bayer Aktiengesellschaft from a “hold” rating to a “buy” rating in a research report on Thursday, July 2nd. Jefferies Financial Group upgraded shares of Bayer Aktiengesellschaft to a “hold” rating in a research report on Friday, May 29th. DZ Bank raised shares of Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a report on Tuesday, May 19th. Finally, Zacks Research upgraded shares of Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research report on Friday, July 10th. Two research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, Bayer Aktiengesellschaft currently has a consensus rating of “Buy”.

Bayer Aktiengesellschaft Trading Down 0.4%

Shares of OTCMKTS:BAYRY traded down $0.06 during trading on Thursday, reaching $14.18. 815,770 shares of the company traded hands, compared to its average volume of 1,240,838. The company has a current ratio of 1.05, a quick ratio of 0.70 and a debt-to-equity ratio of 1.06. Bayer Aktiengesellschaft has a 52-week low of $7.31 and a 52-week high of $15.23. The business’s fifty day moving average is $12.49 and its 200-day moving average is $12.11. The firm has a market capitalization of $55.73 billion, a price-to-earnings ratio of -27.80, a P/E/G ratio of 4.39 and a beta of 0.55.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last posted its earnings results on Tuesday, August 4th. The company reported $0.29 EPS for the quarter, topping the consensus estimate of $0.23 by $0.06. Bayer Aktiengesellschaft had a negative net margin of 3.80% and a positive return on equity of 17.00%. The firm had revenue of $12.53 billion during the quarter, compared to analysts’ expectations of $12.31 billion. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS. As a group, analysts forecast that Bayer Aktiengesellschaft will post 1.27 EPS for the current year.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.